台灣中部地區某區域醫院非酒精性脂肪肝疾病與肥胖相關因子之研究

Non-Alcoholic Fatty Liver Disease and Obesity-Associated Factors: A Study in a Regional Hospital in Mid-Taiwan

10.7023/TJFM.200612.0215

蔡崇煌(Chung-Huang Tsai)；李怡慶(Yii-Ching Lee)；羅永杰(Yung-Chieh Ro)；周俊德(Chun-Te Chou)

non-alcoholic fatty liver disease ； waist circumference ； alanine aminotransferase ； triglyceride ； hepatitis C virus

台灣家庭醫學雜誌

16卷4期（2006 / 12 / 01）

215 - 225

繁體中文

Non-alcoholic fatty liver disease (NAFLD) may progress to liver fibrosis, cirrhosis, and even end stage liver disease. The aim of the present study was to investigate the relationship between NAFLD and obesity-associated factors among those subjects who underwent health examinations in a regional hospital in Taichung between March 2004 and February 2005. Subjects who drank an average of ＜20 grams of alcohol per day were excluded. A total of 700 participants had an abdominal ultrasonographic examination using a TOSHIBA A220 (convex probe; 3.75MHz), of whom 33.1% of the subjects were diagnosed with NAFLD. Of all subjects, 10.9% were hepatitis B virus carriers and 4.6% were positive for hepatitis C virus. Chi-square analysis showed that increased age, high blood pressure, central obesity, impaired fasting glucose or diabetes mellitus, high triglyceride levels, high total cholesterol levels, low levels of high density lipoprotein-cholesterol, high levels of low density lipoprotein-cholesterol, high aspartate aminotransferase levels, high alanine aminotransferase levels, and hyperuricemia were all associated with NAFLD, and all of these measures reached statistical significance (p＜0.001). The subjects with negative anti-hepatitis C antibody titers had features of NAFLD (p=0.044). The result of a stepwise multivariate logistic regression model revealed that age (Odds Ratio [OR]=1.1; 95% confidence interval [CI] 1.0-1.1), central obesity (OR=4.2; 95% CI 2.8-6.4), impaired fasting glucose or diabetes mellitus (OR=2.3; 95% CI 1.3-4.0), hypertriglyceridemia (OR=2.5; 95% CI 1.7-3.7) and high alanine aminotransferase (OR=2.6; 95% CI 1.6-4.2) were more commonly associated with NAFLD. However, subjects with hepatitis C virus infection weren't predisposed to NAFLD (OR=0.2; 95% CI 0.1-0.7). In conclusion, physicians should consider the possibility of NAFLD, if patients are elderly, have central obesity, impaired fasting glucose or diabetes mellitus, high triglyceride levels, high alanine aminotransferase levels, and negative anti-hepatitis C antibody titers.

Non-alcoholic fatty liver disease (NAFLD) may progress to liver fibrosis, cirrhosis, and even end stage liver disease. The aim of the present study was to investigate the relationship between NAFLD and obesity-associated factors among those subjects who underwent health examinations in a regional hospital in Taichung between March 2004 and February 2005. Subjects who drank an average of ＜20 grams of alcohol per day were excluded. A total of 700 participants had an abdominal ultrasonographic examination using a TOSHIBA A220 (convex probe; 3.75MHz), of whom 33.1% of the subjects were diagnosed with NAFLD. Of all subjects, 10.9% were hepatitis B virus carriers and 4.6% were positive for hepatitis C virus. Chi-square analysis showed that increased age, high blood pressure, central obesity, impaired fasting glucose or diabetes mellitus, high triglyceride levels, high total cholesterol levels, low levels of high density lipoprotein-cholesterol, high levels of low density lipoprotein-cholesterol, high aspartate aminotransferase levels, high alanine aminotransferase levels, and hyperuricemia were all associated with NAFLD, and all of these measures reached statistical significance (p＜0.001). The subjects with negative anti-hepatitis C antibody titers had features of NAFLD (p=0.044). The result of a stepwise multivariate logistic regression model revealed that age (Odds Ratio [OR]=1.1; 95% confidence interval [CI] 1.0-1.1), central obesity (OR=4.2; 95% CI 2.8-6.4), impaired fasting glucose or diabetes mellitus (OR=2.3; 95% CI 1.3-4.0), hypertriglyceridemia (OR=2.5; 95% CI 1.7-3.7) and high alanine aminotransferase (OR=2.6; 95% CI 1.6-4.2) were more commonly associated with NAFLD. However, subjects with hepatitis C virus infection weren't predisposed to NAFLD (OR=0.2; 95% CI 0.1-0.7). In conclusion, physicians should consider the possibility of NAFLD, if patients are elderly, have central obesity, impaired fasting glucose or diabetes mellitus, high triglyceride levels, high alanine aminotransferase levels, and negative anti-hepatitis C antibody titers.

1. 陳進明、廖浩欽、王豐林、李強忠、林忠順(2003)。脂肪肝有無併肝生化異常相關因子之探討－以某醫學中心勞工健檢結果為例。台灣家醫誌，13，53-60。
   連結：
2. Adinolf LE,Utili R,Andreana A(2004).Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.Dig Dis Sci,46,1677.
3. Angulo P,Lindor KD(2002).Non-alcoholic fatty liver disease.J Gastroenterol Hepatol,17,186-190.
4. Anonymous(2001).Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA,285,2486-2497.
5. C-F Jan,C-J Chen,Y-H Chiu(2006).A population-based study investigating the association between metabolic syndrome and Hepatitis B/C infection (Keelung Community-based Integrated Screening Study No. 10).Int J Obes,30,794-799.
6. Cross R,Jewell S,Rosenberg W(2004).HepCgen (r) HCV Genotyping for Treatment (by Real Time PCR).Clin Chem,50,2228.
7. Day CP,James OFW(1998).Steatohepatitis: a tale of two `hits`?.Gastroenterology,114,842-845.
8. Diehl AM,Goodman Z,Ishak KG(1988).Alcohol-like liver disease in nonalcoholics. A clinical and histological comparison with alcohol-induced liver injury.Gastroenterology,95,1056-1062.
9. Falck-Ytter Y,Younossi ZM,Marchesini G,McCullough AJ(2001).Clinical features and natural history of non-alcoholic steatosis syndromes.Semin Liver Dis,21,17-26.
10. Hanley AJG,Williams K,Festa A(2004).Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.Diabetes,53,2623-2633.
11. Inoue S,Zimmet P,Caterson I(2000).The Asia-Pacific Perspective: Redefining Obesity and Its Treatment.Australia:Health Community Australia.
12. Jonas MM(2004).Nonalcoholic fatty liver disease.Adolescent Medicine Clinics,15,159-173.
13. Lonardo A,Adinolfi LE,Loria P,Carulli N,Ruggiero G,Day CP(2004).Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease.Gastroenterology,126,586-597.
14. Marchesini G,Brizi M,Bianchi G(2001).Nonalcoholic fatty liver disease: A feature of the metabolic syndrome.Diabetes,50,1844-1850.
15. Marchesini G,Brizi M,Bianchi G,Tomassetti S,Zoli M,Melchionda N(2001).Metformin in non-alcoholic steatohepatitis.Lancet,358,893-894.
16. Matteoni CA,Younossi ZM,Gramlich T(1999).Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity.Gastroenterology,116,1413-1419.
17. Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,Oliver D,Bacon BR(2003).Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.Hepatology,38,1008-1017.
18. Ong JP,Younossi ZM,Speer C,Olano A,Gramlich T,Boparai N(2001).Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.Liver,21,266-271.
19. Osawa H,Mori Y(1996).Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical echo amplitudes.J Clin Ultrasound,24,25-29.
20. Ramesh S,Sanyal AJ(2004).Hepatitis C and nonalcoholic fatty liver disease.Semin Liver Dis,24,399-413.
21. Ratziu V,Giral P,Charlotte F.Liver fibrosis in over-weight patients.
22. Sattar N,Scherbakova O,Ford I(2004).Elevated Alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and c-reactive protein in the west of Scotland coronary prevention study.Diabetes,53,2855-2860.
23. Sharma P,Balan V,Hernandez J(2004).Hepatic steatosis in hepatitis c virus genotype 3 infection: does it correlate with body mass index, fibrosis, and hcv risk factors?.Dig Dis Sci,49,1-25.
24. Shien MJ,Lin WL,Chiang IJ(1996).The predictive value of body weight and body mass index (BMI) in the ultrasound-diagnosed fatty liver.Biomed Engineering,8,38-42.
25. Teli MR,James OF,Burt AD,Bennett MK,Day CP(1995).The natural history of nonalcoholic fatty liver: a follow-up study.Hepatology,22,1714-1719.
26. Tommaso LD,Macchia S,Morandi L(2003).Correlation between histologic staging, hepatitis C virus genotypes and clinical features in HCV chronic hepatitis: Evidence of a new pattern.Int J Surg Pathol,11,197-199.
27. Unger RH(2003).Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome.Endocrinology,144,5159-5165.
28. Watson AM,Poloyac SM,Howard G,Blouin RA(1999).Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse.Drug Metab Dispos,27,695-700.
29. Wu CH,Lee MF,Kuo HS(1997).Distribution of hepatitis C virus genotypes among blood donors in Taiwan.J Gastroenterol Hepatol,12,625-628.
30. Younossi ZM(1999).Non-alcoholic fatty liver disease.Curr Gastroenterol Rep,1,57-62.
31. Younossi ZM,Diehl AM,Ong JP(2002).Nonalcoholic fatty liver disease: an agenda for clinical research.Hepato1ogy,35,746-752.
32. Younossi ZM,McCullough AJ,Ong JP(2004).Obesity and non-alcoholic fatty liver disease in chronic hepatitis.C. J Clin Gastroenterol,38,705-709.
33. Yu ML,Chuang WL,Lu SN,Chen SC,Wang JR,Lin ZY,Hsieh MY,Wang LY,Chang WY(1996).The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan.Kaohsiung J Med Sci,1211,605-612.
34. 黃義雄、李文宗(1997)。老年人脂肪肝的相關因素。中華家醫誌，7，86-93。
35. 楊逸菊、謝蕙宜、陳振寬、林敏雄(2000)。台灣成年人非酒精性脂肪肝相關因子之分析。中華家醫誌，10，59-66。
36. 葉慶輝、葉淑娟(2004)。勞工健檢中脂肪肝之相關因素探討。中華職業誌，11，57-70。
37. 賴世偉、黃金財、李佳雯(2004)。健檢民眾B型及C型肝炎盛行率之描述性分析：以某醫學中心為例。中台灣醫誌，9，64-68。